Sutro Biopharma Cash Flow Statement Analysis

Operating, investing, and financing activities in millions USD

Scroll to see more
Cash flow statement showing operating, investing, and financing activities for Sutro Biopharma, Inc. (STRO) - Annual data in millions USD
BreakdownFY 2024FY 2023FY 2022FY 2021FY 2020FY 2019
Period EndingDec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019
Operating Activities
Net Income-227.46-106.79-119.20-105.54-32.13-55.74
Depreciation & Amortization7.226.825.697.584.793.32
Stock Based Compensation24.6924.9126.3023.2411.920.00
Change in Working Capital8.90-34.38104.41-23.35-14.29-23.06
Change in Accounts Receivable27.46-28.965.34-6.900.740.00
Change in Accounts Payable0.714.81-1.232.71-1.140.00
Change in Other Working Capital-19.2716.822.921.773.870.00
Other Operating Activities-4.8816.822.9236.99-28.9810.67
Net Cash from Operating Activities-191.54-111.623.55-81.68-67.80-65.02
Investing Activities
Capital Expenditures-3.10-4.32-7.86-15.32-7.130.00
Purchases of Investments-461.52-460.30-216.67-82.007.640.00
Sales/Maturities of Investments683.13460.69189.50-97.320.60-51.13
Other Investing Activities0.000.000.01151.41131.35145.10
Net Cash from Investing Activities218.51-3.92-35.02-97.320.60-51.13
Financing Activities
Debt Repayment-4.08-12.50-9.380.00-10.00-5.00
Common Stock Issued96.5311.9756.271.77252.700.93
Common Stock Repurchased0.00-0.49-0.46-0.99-0.310.00
Other Financing Activities1.61135.72-0.46-0.99-0.31-0.30
Net Cash from Financing Activities94.05137.5548.313.26269.25-4.18
Summary
Net Change in Cash121.0222.0116.84-175.74202.05-120.34
Cash at Beginning of Period70.1448.1331.29207.024.98125.31
Cash at End of Period191.1670.1448.1331.29207.024.98
Free Cash Flow-194.64-115.93-4.31-81.68-67.80-65.02
Supplemental Disclosures
Interest Paid0.311.131.872.051.681.05
Income Taxes Paid17.520.380.000.100.000.00